Andrx Reorganizes its Branded Operations.

Business Editors/Health & Medical Writers

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Dec. 3, 2003

Andrx Corporation ("Andrx" or "Company") (Nasdaq:ADRX) announced today that it has effected a number of actions in its brand operations. The Company intends to pursue fewer early stage brand development opportunities and will increase its utilization of clinical research organizations (CROs) for its later stage development efforts. This shift in focus has resulted in a reduction in personnel employed in the Company's clinical operations in New Jersey and Florida, and the promotion of Josephine Cucchiaro. Ph.D. and Judith Jaeger, M.D. to Vice President positions, overseeing the reorganized brand business unit's clinical development and safety operations. The Company has also reorganized its brand sales structure to now comprise 325 primary care territories, which it will presently serve through its sales force of approximately 250 representatives. The size of the Company's brand sales force will be increased in 2004 to prepare for the Company's expected launch of Cardura(R) XL, pursuant to the recently announced agreement with Pfizer Inc., which the Company anticipates marketing to urologists as well as primary care physicians. Andrx remains committed to the brand business and will continue to utilize its drug delivery technologies and formulation capabilities to improve the efficacy or other characteristics of existing pharmaceutical products. Andrx also intends to continue to pursue business development opportunities that will leverage and otherwise optimize the Company's brand organization, and will consider adjusting the size and utilization of its sales force for such opportunities.

About Andrx Corporation

Andrx Corporation develops and commercializes: bioequivalent versions of controlled-release brand name pharmaceuticals, using its proprietary drug delivery technologies; bioequivalent versions of specialty, niche and immediate-release pharmaceutical products, including oral contraceptives; and brand name or proprietary controlled-release formulations of existing immediate-release or controlled-release drugs where it believes the application of Andrx's drug delivery technologies may improve the efficacy or other characteristics of those products. Andrx also has distribution operations, which purchase primarily generic pharmaceuticals manufactured by third parties and sell them primarily to independent pharmacies, pharmacy chains, pharmacy buying groups and, to a lesser extent, physicians' offices.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the Company's dependence on a relatively small number of products, licensing revenues, the timing and commercial success of Altocor(R) and its future brand product launches, including Cardura XL, Fortamet(TM) and its Valproate product, government regulation, competition, and manufacturing results. Andrx Corporation is also subject to other risks detailed herein or detailed from time to time in its filings with the U.S. Securities and Exchange Commission. Andrx disclaims any responsibility to update the statements contained herein.

This release and additional information about Andrx Corporation are also available on the Internet at: http://www.andrx.com.